EDT Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $48.51, indicating a -0.84% shift from the previous trading day.

Longer Term Trading Plans for CRSP. Buy CRSP near 40.82 target 52.08 stop loss @ 40.7 Details; The technical summary data ...

Prof. Hendrik Bessembinder showed that the vast majority of gains from the US stock market came from only a few selected stocks: Four out of every seven common stocks that have appeared in the CRSP ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other promising biotech stocks. Biotechnology stocks are known for their high risk ...

In a report released today, Joon Lee from Truist Financial reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report).

The Third Avenue Small-Cap Value Fund returned +8.35% during Q3 2024 vs. +10.15% for the Fund’s benchmark index. Click here ...

There's never a dull moment if you're a fan of Cathie Wood. The aggressive growth investor is the co-founder, CEO, and stock picker at Ark Invest. She publishes her daily transactions at the end of ...

Given this risk, we thought we'd take a look at whether CRISPR Therapeutics (NASDAQ:CRSP) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn as ...